A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer
Costa R, Zaman S, Sharpe S, Helenowski I, Shaw C, Han H, Soliman H, Czerniecki B. A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer. Drug Design Development And Therapy 2019, 13: 309-316. PMID: 30679903, PMCID: PMC6338114, DOI: 10.2147/dddt.s188925.Peer-Reviewed Original ResearchConceptsChills/rigorsInjection site reactionsAbsolute riskAdverse eventsHER2 vaccinesSite reactionsTreatment-related serious adverse eventsLarge-scale prospective clinical trialsGrade 3/4 adverse eventsAvailable clinical trial dataHuman epidermal growth factor receptor 2Left ventricle ejection fractionEpidermal growth factor receptor 2Treatment-related deathsSerious adverse eventsGrowth factor receptor 2Prospective clinical trialsVentricle ejection fractionModest clinical efficacyTreatment of patientsClinical trial dataFactor receptor 2Adequate safety assessmentEvidence of heterogeneityGrade fatigue